Академический Документы
Профессиональный Документы
Культура Документы
US
Taiwan
Philippines
Hong Kong
Yemen
Singapore
Pakistan
Iran
Kenya
Myanmar ; etc
Country Evaluation
After country selection then evaluate the country through the countrys GDP, PPP, Disposable
income population etc. and the weights of the country also considered in-country evaluation. The
selective country is helpful or not. If helpful how it will be helpful is also considerable incountry evaluation point.
1. Ease of profit
repatriation
2.
Indices
A component of the Economic
Freedom of the WorldIndex
called restrictions in foreign
capital market
exchange/index of capital
controls among 13 IMF
categories
Growth of real gross domestic
product
Sources
http://data.worldbank.org/
World Bank World Development
3.
PPP
Indicators 2016
http://data.worldbank.org/indicator/NY.G
DP.PCAP.PP.CD
4.
Government
Stability
5.
Gross national
Product
The
global
Governance
economy
Worldwide
Research
Indicators
Dataset
http://www.theglobaleconomy.com/ranki
ngs/wb_political_stability/
6.
Disposable Income
have
find
out
from
http://www.numbeo.com/cost-ofliving/country_price_rankings?
itemId=105
7.
Population
The
8.
Inflation
global
Governance
economy
Worldwide
Research
Indicators
Dataset
http://data.worldbank.org/indicator/FP.C
PI.TOTL.ZG?view=map
Cultural barrier: Same case of china, without their native language they are not
financial market data and credit information for local companies in china.
Varying business practice: As part of a large, heavily populated and diverse country,
each Chinese province or city will have unique business practices and requirements to
market entry. (ANZ Business, 2016)
Legal Factors
Legal factors help for doing cross-border business. Their acceptance of foreign investors and
their products. And law about that product have comes under legal factors
Problems of Foreign Competition
i. Foreign competitors have more equipment, technology and plant
facilities than that of locally owned firms.
ii. Foreign competitors have their own local market so that they can absorb
some losses here.
iii. Foreign competitors get government help in some cases.
Prospects of Foreign Competition
i. Foreign competitions made the country firms more eligible to face
challenges that arose after the year 2005.
ii. Pharmaceuticals industries will become more efficient in producing
medicine which may save our lives.
iii. The local firms will not face any rigorous problem in foreign countries as
they are accustomed in competition with foreign firms..
Problems of Export
i. Unstable political situation is one of the vital reasons for not achieving
the expectation in export.
ii. Problems of port (both sea and air) hinder the timely export.
iii. Irresponsibility of customs officers is a regular phenomenon which
results in increase on the price and cost of medicine.
iv. Sometimes competition tends to follow unfair promotional activities.
v. Still now, the products of the pharmaceuticals industries of Bangladesh
are not world class.
Prospects of export
i. Competition is increasing the quality of medicinal products.
ii. For surviving in the future, competitive environment is necessary.
iii. Competition reduces monopolistic attitude of the firms. As a result, the
customers will be benefited by getting quality products
iv. Export brings foreign currencies for the country which is helpful for the
reserve of the country.
Problems of Customer Choices
i. One main problem is in producing rare drugs foreign companies are
Key Assumption:
Each year patents on pharmaceutical products expire with annual sales worth billions of dollars.
Data monitor estimates that there are blockbuster drugs coming off-patent by 2007 which have
sales in excess of US $82 billion.
This will be one of the key factors which will help drive generic pharmaceutical growth over the
next decade. Beximco Pharma is seeking for position to take advantage of this growing generic
market by regularly introducing new products in its existing and new markets. Its low
manufacturing cost will provide a competitive edge over our global competitors in any
international generic pharmaceutical market.